-
Mashup Score: 4Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer - 28 day(s) ago
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer https://t.co/dwAFPIsbZ6 #gyncsm #ovariancancer #SGO24 #SGO2024 @SGO_org